Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Galectin Therapeutics stock | 2.73

Own Galectin Therapeutics stock in just a few minutes.


Fact checked

Galectin Therapeutics, Inc is a biotechnology business based in the US. Galectin Therapeutics shares (GALT) are listed on the NASDAQ and all prices are listed in US Dollars. Galectin Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of USD$158.6 million.

How to buy shares in Galectin Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Galectin Therapeutics. Find the stock by name or ticker symbol: GALT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Galectin Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.73, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Galectin Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Galectin Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Galectin Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Galectin Therapeutics's share price has had significant positive movement.

Its last market close was USD$2.73, which is 6.23% up on its pre-crash value of USD$2.56 and 82.00% up on the lowest point reached during the March crash when the shares fell as low as USD$1.5.

If you had bought USD$1,000 worth of Galectin Therapeutics shares at the start of February 2020, those shares would have been worth USD$677.16 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,074.80.

Galectin Therapeutics share price

Use our graph to track the performance of GALT stocks over time.

Galectin Therapeutics shares at a glance

Information last updated 2020-10-20.
Latest market close USD$2.73
52-week range USD$1.5 - USD$4.5
50-day moving average USD$2.7843
200-day moving average USD$2.68
Wall St. target price USD$12
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.418

Buy Galectin Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Galectin Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galectin Therapeutics price performance over time

Historical closes compared with the close of $2.73 from 2020-11-16

1 week (2020-11-23) 7.06%
1 month (2020-10-30) 7.48%
3 months (2020-08-28) 0.37%
6 months (2020-05-29) -9.90%
1 year (2019-11-29) -15.48%
2 years (2018-11-30) -44.74%
3 years (2017-11-30) 15.68%
5 years (2015-11-30) 36.50%

Galectin Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -23.5%
Return on equity TTM -39.69%
Profit margin 0%
Book value $0.609
Market capitalisation USD$158.6 million

TTM: trailing 12 months

Shorting Galectin Therapeutics shares

There are currently 5.3 million Galectin Therapeutics shares held short by investors – that's known as Galectin Therapeutics's "short interest". This figure is 4.1% up from 5.1 million last month.

There are a few different ways that this level of interest in shorting Galectin Therapeutics shares can be evaluated.

Galectin Therapeutics's "short interest ratio" (SIR)

Galectin Therapeutics's "short interest ratio" (SIR) is the quantity of Galectin Therapeutics shares currently shorted divided by the average quantity of Galectin Therapeutics shares traded daily (recently around 498698.21596244). Galectin Therapeutics's SIR currently stands at 10.65. In other words for every 100,000 Galectin Therapeutics shares traded daily on the market, roughly 10650 shares are currently held short.

However Galectin Therapeutics's short interest can also be evaluated against the total number of Galectin Therapeutics shares, or, against the total number of tradable Galectin Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galectin Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Galectin Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1737% of the tradable shares (for every 100,000 tradable Galectin Therapeutics shares, roughly 174 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Galectin Therapeutics.

Find out more about how you can short Galectin Therapeutics stock.

Galectin Therapeutics share dividends

We're not expecting Galectin Therapeutics to pay a dividend over the next 12 months.

Have Galectin Therapeutics's shares ever split?

Galectin Therapeutics's shares were split on a 1:6 basis on 23 March 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Galectin Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Galectin Therapeutics shares which in turn could have impacted Galectin Therapeutics's share price.

Galectin Therapeutics share price volatility

Over the last 12 months, Galectin Therapeutics's shares have ranged in value from as little as $1.5 up to $4.5. A popular way to gauge a stock's volatility is its "beta".

GALT.US volatility(beta: 2.32)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galectin Therapeutics's is 2.3249. This would suggest that Galectin Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Galectin Therapeutics overview

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site